In the article, “Management of COPD Exacerbations,” (March 1, 2010, page 607) the brand name for methylprednisolone administered intravenously was incorrectly listed as Depo-Medrol in the first sentence of the third paragraph in the right-hand column of page 609 and in the last column of Table 5 (page 611). The brand name that should have been listed for intravenous methylprednisolone is Solu-Medrol. Depo-Medrol is the brand name of the long-acting intramuscular formulation. The article has been corrected online.